Phase I trial of anivamersen-pegnivacogin [REG1] for arterial thrombosis in patients undergoing open heart surgery, including coronary artery bypass graft.
Latest Information Update: 31 Dec 2012
Price :
$35 *
At a glance
- Drugs Anivamersen-pegnivacogin (Primary)
- Indications Arterial thrombosis
- Focus Therapeutic Use
- 31 Dec 2012 New trial record